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Sudden cardiac death in young athletes
Evidence supports a systematic screening programme before participation
Which screening strategy should be used to identify 
young athletes at risk for sudden cardiac death is a highly 
controversial matter. For many years the medical com-
munity has disputed the cost effectiveness, feasibility, 
and accuracy of including 12 lead electrocardiography 
in the cardiovascular screening of athletes. Discordant 
recommendations from the American Heart Association 
and the European Society of Cardiology have fuelled 
a global debate about the usefulness of such screening 
in athletes.1 2 In the linked study, Sofi and colleagues 
analyse data from 30 065 Italian athletes who underwent 
a complete pre-participation cardiovascular evaluation 
including resting and exercise electrocardiography.3 
Sudden cardiac death in young athletes (<35 years) is 
caused by a diverse set of structural diseases of the heart 
(such as cardiomyopathies) and electrical defects (such 
as ion channelopathies). In the United States alone, one 
young competitive athlete dies every three days from an 
unrecognised cardiovascular disorder.4 American and 
European authorities have recommended a compre-
hensive pre-participation evaluation, which includes a 
detailed patient and family history and a physical exami-
nation, in all athletes of 12 years or more.1 2
Warning symptoms of underlying cardiovascular dis-
ease—exertional chest pain, syncope or near syncope, 
palpitations, excessive dyspnoea, and unexplained 
 seizures—warrant cessation of sports activity pending 
the results of diagnostic tests. A family history of sudden 
unexplained death or sudden death before the age of 50 
as a result of cardiac problems may also indicate the pres-
ence of a genetic cardiovascular disorder. Unfortunately, 
standardised questionnaires developed to help healthcare 
providers perform a comprehensive pre- participation 
evaluation are underused.5 Thus, important elements of 
the athlete’s history often go unrecognised.
A substantial challenge to screening is that apparently 
healthy asymptomatic athletes may have unsuspected 
cardiovascular disease—death is the first clinical mani-
festation of cardiac disease in up to 60-80% of athletes 
with sudden cardiac death.6 To date, no study monitoring 
sudden cardiac death has shown that a pre-participation 
evaluation based on history and physical examination 
can prevent or detect athletes at risk for sudden death.
The value of adding non-invasive cardiovascular 
tests such as electrocardiography to the screening proc-
ess in athletes is widely debated. In 2007, the Ameri-
can Heart Association reaffirmed its recommendations 
against universal electrocardiographic screening in ath-
letes, citing a low prevalence of disease, poor sensitiv-
ity, high false positive rate, poor cost  effectiveness, and 
a lack of clinicians to interpret the results.1
In contrast, the European Society of Cardiology, 
International Olympic Committee, and the governing 
associations of several US and international professional 
sports leagues endorse the use of electrocardiography 
in the pre-participation screening of athletes.2 These 
recommendations are supported by studies showing 
that electrocardiography is more sensitive than history 
and physical examination alone at identifying athletes 
with underlying cardiovascular disease.7-10 In 1998, one 
study found that electrocardiography had a 77% greater 
power than history and physical examination to detect 
hypertrophic cardiomyopathy.9 In 2006, another study 
reported data from a national pre-participation screening 
programme in Italy in 42 386 athletes over 25 years.8 It 
found that disqualification on the basis of a standardised 
history, physical examination, and electrocardiography 
produced a 10-fold reduction in the incidence of sud-
den cardiac death in young competitive athletes, and 
an 89% reduction of sudden cardiac death as a result of 
cardiomyopathy.8 Although only 0.2% of athletes were 
disqualified for potentially lethal cardiovascular condi-
tions, the study reported a 7% false positive rate and a 
2% overall disqualification rate.8 This raised concerns 
that adopting such a programme would lead to an unac-
ceptable number of disqualifications in athletes with low 
risk of sudden cardiac death.
Recent studies have refined the electrocardiogra-
phy criteria used to distinguish normal from abnormal 
results—producing lower false positive rates. 10-12 A study 
of 2720 athletes and physically active schoolchildren in 
the United Kingdom reported that only 1.5% of those 
screened had a positive electrocardiogram.10 Another 
study reported preliminary findings of electrocardio-
graphic screening in 9125 young adults (age 14-18) from 
the US and found that only 2% of tests were abnormal.11 
These studies indicate that electrocardiographic screen-
ing in athletes results in an acceptable proportion of 
abnormal findings that can be of clinical significance.
The combined disease prevalence of all cardio-
vascular disorders that predispose young athletes to 
sudden cardiac death is around 0.3% (1/333).1 This 
estimate is confirmed by several studies using elec-
trocardiographic screening in athletes with reported 
true positive rates of 0.2-0.4%.7 8 10 The consistency 
of these results across several studies in three differ-
ent countries suggests that such screening may have 
similar value in different  populations.
An important element of Sofi and colleagues’ study 
is that only a small proportion (1.2%) of athletes had 
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Imported malaria in the UK
Is rising because of failure to comply with prophylaxis or to seek  
travel health advice
distinct abnormalities identified on resting electrocar-
diography. As a result, false positives were few. Impor-
tantly, 153 of the 159 true positives involving athletes 
ultimately disqualified from sport with an identified 
cardiovascular disorder would have been overlooked 
on history and physical examination alone. 3 Thus, 
although a detailed personal and family history and 
physical examination will detect an important but lim-
ited number of athletes with underlying cardiovascular 
disease, adding electrocardiography to the screening 
process will detect more athletes with silent cardiovas-
cular disorders at risk of sudden death. 
The existing evidence supports a systematic pre-
participation screening programme for all competitive 
athletes, using a comprehensive personal and family his-
tory questionnaire, physical examination, and screening 
electrocardiography to identify those at risk.
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Malaria is endemic in more than 105 countries. 
With travel predicted to grow to nearly 1.6 billion 
 international arrivals by 2020, travellers will be at 
increased risk of exposure.1 2 The linked observational 
study by Smith and colleagues substantiates the public 
health concerns regarding the prevention of malaria in 
migrant families in the United Kingdom.3 4 The authors 
report that cases of imported malaria significantly 
increased between 1987 and 2006, with an increasing 
proportion attributable to Plasmodium falciparum rather 
than  Plasmodium vivax.
The increase in cases of imported malaria is not unex-
pected. It reflects the increase in the number of visits 
abroad by UK residents—70.5 million in 2007—together 
with a 150% increase in UK residents travelling to 
malaria endemic areas during the past decade.5 One 
notable change is that with improved vector control in 
Asia, most cases are now acquired in Africa. As severe 
acute respiratory syndrome showed, 21st century threats 
to global public health and travel are inextricably inter-
linked, and they present ready opportunities for the 
rapid spread of infectious disease.6
Although people visiting friends and relatives formed 
the largest group returning with malaria during 2007, 
business and holiday travel accounted for 5% and 14% 
of cases.4 People visiting friends and relatives are at par-
ticular risk—despite a 12% fall in the number of malaria 
cases reported in UK travellers during 2007, 72% of 
cases were in such people.4 7
European sentinel surveillance data and other studies 
worldwide have reported up to 10 000 cases of imported 
malaria in industrialised countries as a result of interna-
tional travel, with a case fatality of around 1%.8 9 The 
increase in cases in the UK reported by Smith and col-
leagues occurred despite the availability for decades of 
effective methods of malaria prevention.3 People visiting 
friends and relatives accounted for 64.5% of all reported 
cases of malaria, and travel to West Africa accounted 
for 76% of cases in this high risk group.3 Large clusters 
of P falciparum cases were located in London, mirror-
ing UK migrant demography. The sustained increase in 
migration to the UK has contributed to the increasing 
incidence of imported malaria, as more migrant families 
travel to countries of their ethnic origin, where malaria 
is endemic. The study probably underestimates the true 
burden of malaria in UK travellers, and unless migra-
tion patterns to the UK change, this can be expected 
to increase.
Failure to comply with prophylaxis or to seek travel 
health advice mostly explains the increased risk of expo-
sure and cases of malaria in travellers, particularly those 
visiting friends and relatives. Historically, the problem 
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for travel health practitioners recommending malaria 
prophylaxis for travel to Africa and Asia has been the 
adverse publicity regarding this treatment. In addition, 
many people visiting friends and relatives underestimate 
their risk of exposure to travel related illness, especially 
malaria, despite not having lived in an endemic area for 
many years.10 This is a dangerous presumption. Other 
reasons for the reported increase include inaccessibility 
of travel health advice, over the counter purchase of 
inappropriate prophylaxis, and purchase of inexpen-
sive (and sometimes counterfeit11) prophylaxis at the 
 destination.
Substantial improvements in malaria prophy-
laxis have aided compliance greatly. Health Protec-
tion Agency figures on stated malaria prophylaxis in 
imported malaria cases together with prescription data 
over the same four year period suggest that travellers 
prescribed atovaquone plus proguanil are less likely to 
contract malaria than those given mefloquine or doxy-
cycline ( JN Zuckerman, unpublished data).
Smith and colleagues report a significant decrease 
in imported cases of P vivax after travel to the Indian 
subcontinent, a result of successful vector eradication 
in many urban areas. Pursuing a similar policy and 
achieving the millennium goals in Africa may reduce 
the incidence of malaria in endemic areas and improve 
the health of populations, while also reducing the risk of 
malaria to travellers, all of which may negate the neces-
sity for prophylaxis in the future.
What else can we do? Healthcare practitioners 
involved in advising travellers about preventing malaria 
should follow the clear and concise guidelines on malaria 
prevention for UK travellers.12 Studies of people visiting 
friends and relatives aimed at identifying the pertinent 
factors such as cultural beliefs, knowledge, and attitude 
towards malaria prevention would help understand how 
best to impart health education through targeted com-
munication and the use of innovative techniques.
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Genetic engineering in athletes
Safeguards are needed before the hypothetical threat becomes a reality
Athletes who want to maximise their performance are 
continually tempted to use illegal drugs to gain com-
petitive advantage and to aid recovery from training 
and injuries. Recent revelations of widespread doping 
arising from investigations of the distribution of the 
anabolic steroid tetrahydrogestrinone by the American 
company BALCO (Bay Area Laboratory Co-operative) 
demonstrate the extent of this problem in world class 
athletes.1
Some commentators have raised concerns that 
genetic modification or “gene doping” will be the 
next step in the search for enhanced performance.2-5 
These concerns are based on some impressive studies 
in genetically modified rodents where manipulation of 
individual genes has increased muscle mass, muscle 
strength, or running endurance, depending on the gene 
that was manipulated. Reviews of these animal studies 
conclude that such genetic manipulations could also 
improve human athletic performance.6 7
How likely is it that athletes will use genetic modifica-
tion? About 10% of athletes have used existing drugs,8 
so it is likely that some will be tempted to experiment 
with genetic modification. However, translating studies 
performed in rodents into effective treatments in humans 
will not be easy. Some of the rodent studies were per-
formed in transgenic mice in which the genetic modifica-
tion was introduced into the germline and transmitted 
from one generation to the next. For practical and ethical 
reasons it is not possible to do this in humans.
Widespread genetic modification of somatic rather 
than germline tissues can be achieved in mice by using 
modified viruses to deliver the genetic modification, 
but only when used at very high doses. Scaling up such 
doses from a 25 g mouse to a 75 kg human will prove 
challenging, both in terms of the facilities needed to 
generate such viral vectors and the potential difference 
in immune responses to such viruses between mice and 
humans. It is also not known how well these vectors 
will work in humans.
Current clinical trials—for example, those targeted 
at muscular dystrophies—use only small amounts of 
these viral vectors, and they are early stage safety trials 
that will not tell us whether we can achieve the high 
efficiencies needed to improve muscle function.9 It 
will be many years before agents for gene therapy are 
available for general clinical use.
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Could black market laboratories generate the neces-
sary viral vectors? Many laboratories can make small 
amounts suitable for cell cultures and a few experiments 
in mice, but it would be a major logistical exercise to 
produce high quality preparations in bulk. If this were 
possible, athletes would be running considerable risks. 
Activation of the innate immune system by a relatively 
high dose of viral vector caused the death of a patient 
in a clinical trial in 1999. The man, who had ornithine 
transcarbamylase (OTC) deficiency, developed dissemi-
nated intravascular coagulation and organ failure after a 
delivery of a relatively high dose of recombinant adeno-
virus carrying the OTC gene into the hepatic artery.10
Interfering with genes that could increase athletic per-
formance carries substantial health risks. For example, 
high levels of growth hormone and insulin-like growth 
factor-I have been associated with the development of 
cancers, and overexpression of erythropoietin can lead 
to stroke and heart failure. Other genes such as those 
regulating specific aspects of muscle physiology have 
not been studied for long enough to know what health 
risks might be associated with their long term use.
What needs to be put in place in anticipation of 
potential gene doping? Athletes will be less tempted 
to consider it if tests are in place that could potentially 
detect such genetic modification. Some aspects that are 
specific to gene doping make detection more likely, 
even without the use of complicated diagnostic tests. 
Firstly, proteins expressed in the athlete after gene 
transfer are sometimes different from the normal pro-
tein. For example, erythropoietin is normally produced 
in the kidney and stimulates red blood cell production, 
but after transfer of the erythropoietin gene into muscle 
changes in the post-translational modification of the 
protein would enable doping to be detected.11
Secondly, athletes are aware of the time needed for 
current performance enhancing drugs to clear from the 
system, which is why testing outside of competitions 
is so important in the fight against doping. One of the 
disadvantages of gene doping is that it will be more 
difficult for athletes to tailor their treatments to avoid 
detection. Thirdly, although gene expression can be 
controlled after gene transfer, this requires the use of 
drugs that can readily be detected. Other approaches 
that are being investigated are the development of a 
sensitive test for transgenic DNA and protein or gene 
profiling of athletes over their competitive lifetime.12
Although at present gene doping is a threat rather 
than a reality, it is important to put safeguards in place 
that will prevent athletes from being tempted not only 
to cheat but to put their health at substantial risk.
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More than 25 million people worldwide have dementia, 
with a new case developing every seven seconds.1 While 
putative disease modifying agents are being developed, 
we are limited to symptomatic treatments for cognitive 
and non-cognitive features. Non-cognitive symptoms—
referred to as behavioural and psychological symptoms 
of dementia—including agitation, psychosis, depression, 
and aggression, occur in up to half of those with demen-
tia in the community and an even higher proportion in 
residential care. Antipsychotics have been widely pre-
scribed off licence for these symptoms, and 20-50% of 
people with dementia in institutional care receive them.2 
What is the evidence for their efficacy?
Several placebo controlled, randomised controlled 
trials (RCTs), especially of newer “atypical” antipsychot-
ics like risperidone, show an improvement in agitation, 
aggression, and psychosis.3 But, even before current 
concerns over their side effects, the strength of the evi-
dence supporting widespread prescribing in dementia 
was questioned. Efficacy is modest, and most studies 
have assessed behavioural and psychological symptoms 
of dementia as a general outcome rather than targeting 
specific symptoms.
Side effects include extrapyramidal features, seda-
tion, metabolic disturbances, increased cognitive 
impairment, and severe sensitivity reactions in demen-
tia with Lewy bodies. In 2004 it emerged that the risk 
of cerebrovascular events and stroke was three times 
higher in people treated with the atypicals olanzapine 
and risperidone. A subsequent meta-analysis showed 
increased mortality in people treated with atypical 
antipsychotics compared with placebo, with a number 
needed to harm of around 100.4
These findings combined with high prescribing rates 
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for people with dementia led to warnings about the use of 
these drugs in many countries. In the United Kingdom, 
the Committee on Safety of Medicines went further than 
most to advise that “risperidone or olanzapine should 
not be used for the treatment of behavioural symptoms 
of dementia.”5 Subsequently, patients had their drugs 
withdrawn or were switched to typical antipsychotics, 
often without considering individual circumstances. This 
led to further guidance from professional organisations 
supporting the continued use of atypical antipsychotics 
in some circumstances.6
So where are we now? Cohort studies suggest that 
typical antipsychotics have a similar cerebrovascu-
lar risk to atypical antipsychotics, and possibly even 
higher mortality.7 8 So switching from atypical antipsy-
chotics to typical antipsychotics is unlikely to be a sen-
sible strategy. Questions over efficacy remain. A large 
pragmatic double blind placebo controlled trial, using 
an outcome measure of “time to treatment discontinu-
ation,” found that the benefits of atypical antipsychot-
ics on efficacy were largely offset by  discontinuation 
because of side effects.9
A recent RCT showed that antipsychotics can be 
safely withdrawn in many people with dementia who 
have taken them for prolonged periods, especially if 
symptoms have largely resolved.10 Staff and environ-
mental factors are important, and targeted training and 
support reduced the use of antipsychotics from 42% to 
23% over one year.2
What are the alternatives to antipsychotics? Non-
pharmacological approaches are often rightly advocated. 
Indeed, careful assessment for comorbid conditions and 
exacerbating factors—including physical illness, pain, 
communication difficulties, and depression—are an essen-
tial part of assessment of behavioural and psychological 
symptoms of dementia. For milder symptoms, watchful 
waiting combined with simple explanation, advice, and 
support may be sufficient. Increased social stimulation 
or personalised music may help, and aromatherapy has 
some evidence base.
However, all these non-pharmacological approaches 
are limited, not only by lack of studies but by the dif-
ficulties in undertaking truly placebo controlled trials, 
combined with an absence of studies in more severe 
behavioural disturbance.11 Cholinesterase inhibitors 
may be useful for symptoms such as apathy and psy-
chosis, consistent with cholinergic deficit as a likely 
neurochemical cause. Initial reports that they may 
reduce agitation, a common and problematic symp-
tom for which antipsychotics are often prescribed, were 
not confirmed by a large non-industry funded RCT, 
which showed no benefit of donepezil over placebo.12 
Post hoc analysis of trials of memantine, an NMDA 
(N-methyl D-aspartate) antagonist, suggest possible ben-
efits on agitation and aggression.13 Evidence for other 
drugs is limited; carbamazepine may help agitation and 
aggression, but no clear consensus exists on the role of 
antidepressants in managing behavioural and psycho-
logical symptoms of dementia.
What conclusions can we draw? Evidence based alter-
natives to antipsychotics are relatively few and limited to 
people with mild to moderate symptoms. In more severe 
cases no treatment or non-evidence based treatment is 
often not a clinical option. Antipsychotics, especially 
atypical ones, have the best evidence base, although their 
efficacy is more modest than previously supposed and 
their side effects more serious. Prescribing rates of up to 
50% for people in residential care cannot be justified. 
However, given the lack of suitable alternatives, it is not 
reasonable to stop prescribing completely.
Current advice, such as that contained in the National 
Institute for Health and Clinical Excellence guidelines 
for dementia, is pragmatic and helpful. Management 
of the symptoms consists of a thorough assessment, to 
search for any modifiable causes. Non-pharmacological 
approaches should be used first, and possible alterna-
tives—like carbamazepine for aggression, cholinesterase 
inhibitors for apathy and psychosis, and memantine 
for agitation—should be considered. Prescription of 
 antipsychotics should be carefully targeted, time limited, 
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A young woman, just making ends meet and coping with 
four children, signed up to a breast cancer study where she 
would have to take two big pills every day for two years 
and show up for numerous frequent tests. Why would she 
put herself through that, wondered the researcher who 
went to obtain her consent. “I’m doing it for my daugh-
ter” said the mother, clearly expecting the study to yield 
usable, meaningful, and accessible evidence that might 
help prevent breast cancer in young women. Would she 
have consented so readily if she knew that some stud-
ies are never published and that many are reported so 
poorly that they are barely read and never used? This tale 
was told by that same researcher, Davina Ghersi, coor-
dinator of the World Health Organization international 
clinical trials registry,1 at a meeting in London last month. 
Dr Ghersi was there to help launch the  EQUATOR 
(enhancing the quality and transparency of health 
research) international network, which seeks to improve 
the quality of scientific publications by promoting trans-
parent and accurate reporting of health research.
Registration, publication, and publicly available report-
ing of health research are already mandated by several 
sponsors and funders,2 3 some legislators,4 and many edi-
tors,5 particularly for clinical trials. The next big challenge 
is to decide when and how to disclose the results of a trial 
at a publicly available research registry, and what should 
go into a minimum dataset.6 Yet even journals, some of 
which have reported research for many decades, are still 
not producing articles that are clear enough to really 
judge a study’s conduct, quality, and importance—let 
alone to allow other researchers to reproduce it or build 
on it. With help from EQUATOR, journals should now 
be able to do a much better job and give authors the spe-
cific guidance they need to write up research properly.
Editors already provide instructions to authors, but this 
advice tends to be either unhelpfully vague and brief or 
comprehensively long and daunting—for instance, the 
BMJ’s advice currently extends to well over 20 000 words 
(http://resources.bmj.com/bmj/authors). The develop-
ment of more than 80 guidelines for reporting different 
study types, many of them labelled by acronyms, adds 
to the confusion. Do authors know where to find these 
guidelines, and do editors and reviewers know how to 
use them? Do you know your MOOSE (meta-analysis 
of observational studies in epidemiology) from your 
STROBE (strengthening the reporting of observational 
studies in epidemiology)?
The EQUATOR website (www.equator-network.
org/) comes to the rescue with a digital library of links 
to reporting guidelines. These guidelines give point by 
point advice that enables researchers to say what they did 
and didn’t do in their study, how they did it, and what 
they found, thus allowing honest discussion of the study’s 
meaning, strengths, and weaknesses. As well as explana-
tory documents, these guidelines usually  incorporate one 
or two tools—a checklist of items that must be reported 
clearly, and a template for a flow chart to show what hap-
pened to participants at each stage of the study.
The oldest and best known of the current guidelines 
is the CONSORT (consolidated standards of reporting 
trials) statement. This has spawned several extensions 
for different types and aspects of randomised control-
led trials, and a plethora of other guidelines have now 
been developed by consensus groups of experts. The 
EQUATOR team has identified these guidelines through 
systematic literature searches, has pulled them together 
in one place, and has grouped them simply by type of 
study—including experimental studies, observational stud-
ies, systematic reviews, qualitative research, economic 
evaluations, quality improvement studies, and industry 
sponsored studies.
This is a real boon for the researcher, reviewer, or edi-
tor with a desire for clarity but a poor memory for acro-
nyms. EQUATOR is a good resource for readers and 
learners too. Although these reporting guidelines are not 
explicitly intended to be critical appraisal tools, anyone 
running a journal club or sitting an exam that might test 
research skills should also find them useful. And the dig-
ital library is just the start of a comprehensive programme 
of work on knowledge translation. Over the next five 
years the EQUATOR network plans to develop much 
fuller online resources, including training materials for 
guideline developers, authors, reviewers, and editors, as 
well as published articles about improving the reporting 
of research. The network also aims to audit, every year 
for the next five years, the quality of reporting in health 
research and the performance of journals in implement-
ing these guidelines.
The BMJ is actively supporting the EQUATOR ini-
tiative. We ask researchers to prepare each research 
article in line with the appropriate reporting guideline 
and to submit each manuscript with the right checklist 
properly completed and, if necessary, the right flow 
chart (http://resources.bmj.com/bmj/authors/ types-of-
article/research) (see box on bmj.com). We will not send 
a research article for external peer review without these, 
thus giving our policy some teeth and helping reviewers 
to understand the study’s conduct and quality
Editors should not, however, use these reporting guide-
lines to reject studies that do not reach some fixed or 
arbitrary threshold for quality. In difficult and new areas 
of research, imperfectly conducted studies often provide 
good enough evidence to change policy or practice or to 
inform the next phase of research. Such studies deserve 
to be published, warts and all, but reporting guidelines 
point out where the warts are and how big they are. Using 
another bodily metaphor, Ian Needleman, director of 
London’s International Centre for Evidence-based Oral 
Health, said at the EQUATOR launch “research report-
ing is too often like swimwear: what it reveals is sugges-
tive; what it conceals is vital.”
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